Cargando…
Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence
BACKGROUND: A treatment-related fluctuation (TRF) in a patient with Guillain-Barré syndrome (GBS) is defined as clinical deterioration within two months of symptom onset following previous stabilization or improvements with treatment. OBJECTIVE: To investigate the clinical characteristics and factor...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academia Brasileira de Neurologia - ABNEURO
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238334/ https://www.ncbi.nlm.nih.gov/pubmed/35195232 http://dx.doi.org/10.1590/0004-282X-ANP-2021-0226 |
_version_ | 1784737027281911808 |
---|---|
author | ALESSANDRO, Lucas CASTIGLIONE, Juan Ignacio BRAND, Patricio BRUNO, Veronica BARROSO, Fabio |
author_facet | ALESSANDRO, Lucas CASTIGLIONE, Juan Ignacio BRAND, Patricio BRUNO, Veronica BARROSO, Fabio |
author_sort | ALESSANDRO, Lucas |
collection | PubMed |
description | BACKGROUND: A treatment-related fluctuation (TRF) in a patient with Guillain-Barré syndrome (GBS) is defined as clinical deterioration within two months of symptom onset following previous stabilization or improvements with treatment. OBJECTIVE: To investigate the clinical characteristics and factors that could increase the risk of relapse of GBS in patients with and without TRFs. METHODS: Retrospective review of medical records of patients (>18 years) with GBS evaluated between January/2006 and July/2019. Demographic and clinical characteristics, ancillary studies, treatment received, and the clinical course of patients with and without TRFs were analyzed. RESULTS: Overall, 124 cases of GBS were included; seven (5.6%) presented TRFs. GBS-TRF cases were triggered more frequently by infectious mononucleosis (28.57 vs. 8.55%; p=0.01). GBS-TRF were initially treated with plasmapheresis more frequently than those without TRF (14.29 vs. 1.70%; p=0.0349). Combined treatment (71.43 vs. 4.27%; p<0.001) and corticosteroids (42.86 vs. 1.71%; p<0.001) were more commonly used in the GBS-TRF group. GBS-TRF patients presented a higher median initial disability score (4 vs. 2; p=0.01). CONCLUSIONS: Patients with GBS triggered by infectious mononucleosis and a high degree of initial disability have higher chances of developing TRFs. Although patients with TRF were treated with plasmapheresis more often, the total number was too low to suggest a link between plasma exchange and TRF. |
format | Online Article Text |
id | pubmed-9238334 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Academia Brasileira de Neurologia - ABNEURO |
record_format | MEDLINE/PubMed |
spelling | pubmed-92383342022-12-08 Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence ALESSANDRO, Lucas CASTIGLIONE, Juan Ignacio BRAND, Patricio BRUNO, Veronica BARROSO, Fabio Arq Neuropsiquiatr Article BACKGROUND: A treatment-related fluctuation (TRF) in a patient with Guillain-Barré syndrome (GBS) is defined as clinical deterioration within two months of symptom onset following previous stabilization or improvements with treatment. OBJECTIVE: To investigate the clinical characteristics and factors that could increase the risk of relapse of GBS in patients with and without TRFs. METHODS: Retrospective review of medical records of patients (>18 years) with GBS evaluated between January/2006 and July/2019. Demographic and clinical characteristics, ancillary studies, treatment received, and the clinical course of patients with and without TRFs were analyzed. RESULTS: Overall, 124 cases of GBS were included; seven (5.6%) presented TRFs. GBS-TRF cases were triggered more frequently by infectious mononucleosis (28.57 vs. 8.55%; p=0.01). GBS-TRF were initially treated with plasmapheresis more frequently than those without TRF (14.29 vs. 1.70%; p=0.0349). Combined treatment (71.43 vs. 4.27%; p<0.001) and corticosteroids (42.86 vs. 1.71%; p<0.001) were more commonly used in the GBS-TRF group. GBS-TRF patients presented a higher median initial disability score (4 vs. 2; p=0.01). CONCLUSIONS: Patients with GBS triggered by infectious mononucleosis and a high degree of initial disability have higher chances of developing TRFs. Although patients with TRF were treated with plasmapheresis more often, the total number was too low to suggest a link between plasma exchange and TRF. Academia Brasileira de Neurologia - ABNEURO 2022-02-21 /pmc/articles/PMC9238334/ /pubmed/35195232 http://dx.doi.org/10.1590/0004-282X-ANP-2021-0226 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | Article ALESSANDRO, Lucas CASTIGLIONE, Juan Ignacio BRAND, Patricio BRUNO, Veronica BARROSO, Fabio Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence |
title | Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence |
title_full | Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence |
title_fullStr | Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence |
title_full_unstemmed | Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence |
title_short | Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence |
title_sort | treatment-related fluctuations in guillain-barré syndrome: clinical features and predictors of recurrence |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238334/ https://www.ncbi.nlm.nih.gov/pubmed/35195232 http://dx.doi.org/10.1590/0004-282X-ANP-2021-0226 |
work_keys_str_mv | AT alessandrolucas treatmentrelatedfluctuationsinguillainbarresyndromeclinicalfeaturesandpredictorsofrecurrence AT castiglionejuanignacio treatmentrelatedfluctuationsinguillainbarresyndromeclinicalfeaturesandpredictorsofrecurrence AT brandpatricio treatmentrelatedfluctuationsinguillainbarresyndromeclinicalfeaturesandpredictorsofrecurrence AT brunoveronica treatmentrelatedfluctuationsinguillainbarresyndromeclinicalfeaturesandpredictorsofrecurrence AT barrosofabio treatmentrelatedfluctuationsinguillainbarresyndromeclinicalfeaturesandpredictorsofrecurrence |